Two of the first patients with cancer treated with chimeric antigen receptor-modified (CAR) T cells have been cancer free for a decade. A new study uses single-cell sequencing technologies to provide a window into the evolution of their CAR T cells over the course of the ten-year remission period.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Melenhorst, J. J. et al. Nature 602, 503–509 (2022).
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. N. Engl. J. Med. 365, 725–733 (2011).
Kalos, M. et al. Sci. Transl. Med. 3, 95ra73 (2011).
Fraietta, J. A. et al. Nature 558, 307–312 (2018).
Grupp, S. A. et al. N. Engl. J. Med. 368, 1509–1518 (2013).
Abramson, J. S. et al. Lancet 394, 839–852 (2020).
Locke, F. L. et al. Lancet Oncol. 20, 31–42 (2019).
Munshi, N. C. et al. N. Engl. J. Med. 384, 705–716 (2021).
Fraietta, J. A. et al. Nat. Med. 24, 563–571 (2018).
Deng, Q. et al. Nat. Med. 26, 1878–1887 (2020).
Locke, F. L. et al. Blood Adv. 4, 4898–4911 (2020).
Shouval, R. et al. J. Clin. Oncol. 40, 369–381 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.V.M. is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital and the University of Pennsylvania (some licensed to Novartis). M.V.M. holds equity in TCR2, Century Therapeutics, Genocea, Oncternal, and Neximmune, and has served as a consultant for multiple companies involved in cell therapies. Consultant for: Adaptimmune, Agenus, Allogene, Arcellx, Astellas, AstraZeneca, Atara, Bayer, BMS, Cabaletta Bio (SAB), Cellectis (SAB), CRISPR Therapeutics, EMD Serono, Genocea, In8bio (SAB), Intellia, GSK, Kite Pharma, Micromedicine/BendBio, Neximmune, Novartis, Oncternal, Sanofi, Synthekine, TCR2 (SAB), Tmunity, Werewolf and WindMIL (SAB). Speaker’s Bureau: none. Grant/Research support: Kite Pharma, Servier, Novartis Stockholder: Century Therapeutics, Genocea, Oncternal, TCR2, 2Seventy Bio. Board of Directors: 2Seventy Bio.
Rights and permissions
About this article
Cite this article
Maus, M.V. A decade of CAR T cell evolution. Nat Cancer 3, 270–271 (2022). https://doi.org/10.1038/s43018-022-00347-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-022-00347-4
This article is cited by
-
SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors
Cellular & Molecular Immunology (2024)
-
Untangling the threads of immunotherapy research
Nature Cancer (2022)
